🔎 Trials Near Me

Beranda › Kanker Kandung Kemih › Georgia

Uji klinis Kanker Kandung Kemih di Georgia

19 studi untuk Kanker Kandung Kemih mencari peserta di lokasi di Georgia.

Kota di Georgia

Teks studi resmi (Bahasa Inggris)

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

  • Emory University, Atlanta
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT06465069

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • Northeast Georgia Medical Center Braselton, Braselton
  • Atlanta VA Medical Center, Decatur
  • Northeast Georgia Medical Center-Gainesville, Gainesville
  • dan 4 lainnya
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 40 hingga 75 · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT05334069

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

  • Grady Health System, Atlanta
  • Emory Proton Therapy Center, Atlanta
  • Emory University Hospital Midtown, Atlanta
  • dan 2 lainnya
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT06770582

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

  • CTCA at Southeastern Regional Medical Center, Newnan
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT07061964

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

  • Emory University Hospital Midtown, Atlanta
  • Emory University Hospital/Winship Cancer Institute, Atlanta
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT03866382

Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

  • Tennessee Oncology, PLLC- Ringgold, Ringgold
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT07421700

A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer

  • Emory University Hospital Midtown, Atlanta
  • Emory University Hospital, Atlanta
  • Emory University, Atlanta
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT07206225

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas

  • The Winship Cancer Institute Emory University, Atlanta
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Sep 2026 · NCT07217171

Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC

  • Emory University, Atlanta
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT06567743

Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer

  • Urology of Greater Atlanta - Sandy Springs, Atlanta
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 21 Agu 2026 · NCT07480356

FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3

  • Emory University Hospital, Atlanta
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 20 Agu 2026 · NCT05614739

Measuring Surgical Recovery After Radical Cystectomy

  • Emory University, Atlanta
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 19 Agu 2026 · NCT03193970

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

  • Grady Health System, Atlanta
  • Emory University Hospital Midtown, Atlanta
  • Emory University Hospital/Winship Cancer Institute, Atlanta
  • dan 1 lainnya
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Agu 2026 · NCT07097142

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

  • Emory University, Atlanta
  • Georgia Cancer Center at Augusta University, Augusta
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 7 Agu 2026 · NCT04752722

Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology

  • Grady Health System, Atlanta
  • Emory University Hospital Midtown, Atlanta
  • Emory University Hospital/Winship Cancer Institute, Atlanta
  • dan 1 lainnya
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Jul 2026 · NCT05756569

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

  • North Georgia Health System, Gainesville
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 40 ke atas · Semua jenis kelamin · Diperbarui 20 Jan 2026 · NCT05366881

Blue Light Cystoscopy With Cysview® Registry

  • Emory University School of Medicine, Atlanta
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Des 2025 · NCT02660645

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Atlanta
  • Massive Bio SYNERGY-AI site, Savannah
Menerima pesertaStudi observasional
Semua usia · Semua jenis kelamin · Diperbarui 28 Okt 2025 · NCT03452774

A Beta-only IL-2 ImmunoTherapY Study

  • Emory - Winship Cancer Institute, Atlanta
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Jul 2025 · NCT05086692

Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.